Mark Guinan
Director/Board Member presso UPHEALTH, INC.
Patrimonio netto: 167 030 $ in data 31/03/2024
Profilo
Attualmente, Mark J. Guinan ricopre la posizione di direttore finanziario e vicepresidente esecutivo presso Quest Diagnostics, Inc. Guinan è anche nel consiglio di amministrazione di Myovant Sciences Ltd., Q Squared Solutions Holdings Ltd. e Roivant Sciences, Inc. In precedenza ha occupato la posizione di Chief Financial Officer & Senior Vice President presso Hill-Rom Holdings, Inc., Vice President-Finance di Global Pharmaceutical Group, Chief Procurement Officer presso Johnson & Johnson e Principal presso Procter & Gamble Co. Mark J. Guinan ha conseguito una laurea presso l'Università di Notre Dame e un MBA presso la Olin Business School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
UPHEALTH INC
0.86% | 31/01/2024 | 160 606 ( 0.86% ) | 167 030 $ | 31/03/2024 |
Posizioni attive di Mark Guinan
Società | Posizione | Inizio |
---|---|---|
UPHEALTH, INC. | Director/Board Member | 05/12/2022 |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Director/Board Member | - |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
Precedenti posizioni note di Mark Guinan
Società | Posizione | Fine |
---|---|---|
MYOVANT SCIENCES LTD. | Director/Board Member | 10/03/2023 |
QUEST DIAGNOSTICS INCORPORATED | Director of Finance/CFO | 11/07/2022 |
HILL-ROM HOLDINGS, INC. | Director of Finance/CFO | 19/07/2013 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2010 |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formazione di Mark Guinan
University of Notre Dame | Undergraduate Degree |
Olin Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
JOHNSON & JOHNSON | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
QUEST DIAGNOSTICS INCORPORATED | Health Services |
UPHEALTH, INC. | Health Services |
Aziende private | 5 |
---|---|
Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. Hospital/Nursing ManagementHealth Services Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL. | Health Services |
Global Pharmaceutical Group | |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Health Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Mark Guinan